Selecta Biosciences Company Profile (NASDAQ:SELB)

About Selecta Biosciences (NASDAQ:SELB)

Selecta Biosciences logoSelecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its product candidates are in various stages of clinical and preclinical development. Its SVP technology encapsulates an immunomodulator in biodegradable nanoparticles to induce antigen-specific immune tolerance to mitigate the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. The Company's lead product candidate, SEL-212, is a combination of a therapeutic enzyme and its SVP technology designed to be the biologic treatment for gout.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:SELB
  • CUSIP: N/A
  • Web: www.selectabio.com
Capitalization:
  • Market Cap: $410.8 million
  • Outstanding Shares: 22,074,000
Average Prices:
  • 50 Day Moving Avg: $17.80
  • 200 Day Moving Avg: $17.80
  • 52 Week Range: $11.95 - $28.00
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.20
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $4.14 million
  • Price / Sales: 106.80
  • Book Value: $3.55 per share
  • Price / Book: 5.64
Profitability:
  • EBIDTA: ($51,160,000.00)
  • Net Margins: -1,277.76%
  • Return on Equity: -88.31%
  • Return on Assets: -57.84%
Debt:
  • Debt-to-Equity Ratio: 0.07%
  • Current Ratio: 5.71%
  • Quick Ratio: 5.71%
Misc:
  • Average Volume: 115,314 shs.
  • Beta: -6.05
  • Short Ratio: 11.66
 

Frequently Asked Questions for Selecta Biosciences (NASDAQ:SELB)

What is Selecta Biosciences' stock symbol?

Selecta Biosciences trades on the NASDAQ under the ticker symbol "SELB."

How were Selecta Biosciences' earnings last quarter?

Selecta Biosciences, Inc. (NASDAQ:SELB) posted its quarterly earnings results on Friday, August, 11th. The company reported ($0.85) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.86) by $0.01. The company had revenue of $0.03 million for the quarter. Selecta Biosciences had a negative net margin of 1,277.76% and a negative return on equity of 88.31%. View Selecta Biosciences' Earnings History.

When will Selecta Biosciences make its next earnings announcement?

Selecta Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Selecta Biosciences.

Where is Selecta Biosciences' stock going? Where will Selecta Biosciences' stock price be in 2017?

3 analysts have issued twelve-month target prices for Selecta Biosciences' shares. Their forecasts range from $25.00 to $32.00. On average, they anticipate Selecta Biosciences' stock price to reach $28.33 in the next year. View Analyst Ratings for Selecta Biosciences.

What are analysts saying about Selecta Biosciences stock?

Here are some recent quotes from research analysts about Selecta Biosciences stock:

  • 1. According to Zacks Investment Research, "Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States. " (8/16/2017)
  • 2. Canaccord Genuity analysts commented, "We are particularly interested in data on antibodies to SEL-212, which we expect to be very clean; that is, we do not expect antibodies to SEL-212. Given the previous data that we have seen, we are expecting SEL-212 to continue positive development with strong ADA suppression and a highly tolerable safety profile." (8/11/2017)
  • 3. Needham & Company LLC analysts commented, "Selecta presented initial Phase II multi-dose data for SEL-212 on its 4Q16 earnings call. We believe this early data is very encouraging as a clinically active monthly dose appears to have been reached. Dosing continues with 2 additional cohorts. The next update is expected at a conference in June. We remain buyers of SELB as we believe they have both a promising clinical candidate in SEL-212 and a broadly applicable platform to induce tolerance to anti-drug antibodies." (3/28/2017)

Who are some of Selecta Biosciences' key competitors?

Who are Selecta Biosciences' key executives?

Selecta Biosciences' management team includes the folowing people:

  • Werner Cautreels Ph.D., Chairman of the Board, President, Chief Executive Officer
  • Omid Farokhzad M.D., Co-Founder, Director
  • David Siewers, Chief Financial Officer, Treasurer
  • Lloyd Johnston Ph.D., Chief Operating Officer, Senior Vice President - Research & development
  • Takashi Kei Kishimoto Ph.D., Chief Scientific Officer
  • David Abraham J.D., Chief Compliance Officer, General Counsel, Corporate Secretary
  • Peter Keller, Chief Business Officer
  • Dmitry Ovchinnikov, Managing Director, SelectaRUS, LLC
  • Earl Sands M.D., Chief Medical Officer
  • Carl L. Gordon Ph.D., Director

When did Selecta Biosciences IPO?

(SELB) raised $64 million in an IPO on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers.

Who owns Selecta Biosciences stock?

Selecta Biosciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vivo Capital LLC (5.91%), JPMorgan Chase & Co. (0.00%), FMR LLC (0.00%), Sphera Funds Management LTD. (0.00%), Vanguard Group Inc. (0.00%) and State Street Corp (0.00%). Company insiders that own Selecta Biosciences stock include Amir Nashat, David Abraham, David Siewers, Edwin M Kania, Jr, Lloyd P Johnston, Nanodimension Management Ltd, Peter Keller, Takashi Kei Kishimoto and Timothy A Springer. View Institutional Ownership Trends for Selecta Biosciences.

Who bought Selecta Biosciences stock? Who is buying Selecta Biosciences stock?

Selecta Biosciences' stock was bought by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Vanguard Group Inc., JPMorgan Chase & Co., Candriam Luxembourg S.C.A., State Street Corp, Northern Trust Corp, Wasatch Advisors Inc. and TIAA CREF Investment Management LLC. Company insiders that have bought Selecta Biosciences stock in the last two years include Amir Nashat, Nanodimension Management Ltd and Timothy A Springer. View Insider Buying and Selling for Selecta Biosciences.

How do I buy Selecta Biosciences stock?

Shares of Selecta Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Selecta Biosciences' stock price today?

One share of Selecta Biosciences stock can currently be purchased for approximately $20.03.


MarketBeat Community Rating for Selecta Biosciences (NASDAQ SELB)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  78 (Vote Outperform)
Underperform Votes:  53 (Vote Underperform)
Total Votes:  131
MarketBeat's community ratings are surveys of what our community members think about Selecta Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Selecta Biosciences (NASDAQ:SELB) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $28.33 (41.45% upside)

Analysts' Ratings History for Selecta Biosciences (NASDAQ:SELB)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/11/2017Canaccord GenuitySet Price TargetBuy$25.00LowView Rating Details
3/28/2017Needham & Company LLCReiterated RatingBuy$28.00HighView Rating Details
12/8/2016Stifel NicolausReiterated RatingBuy$23.00 -> $32.00N/AView Rating Details
(Data available from 9/21/2015 forward)

Earnings

Earnings History for Selecta Biosciences (NASDAQ:SELB)
Earnings by Quarter for Selecta Biosciences (NASDAQ:SELB)
Earnings History by Quarter for Selecta Biosciences (NASDAQ SELB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017($0.87)N/AView Earnings Details
8/11/2017Q2 2017($0.86)($0.85)$0.03 millionViewN/AView Earnings Details
5/11/2017Q1 2017($1.22)($0.82)$0.14 millionViewN/AView Earnings Details
3/27/201712/31/2016($0.25)($0.77)$15.00 million$2.93 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Selecta Biosciences (NASDAQ:SELB)
Current Year EPS Consensus Estimate: $-2.66 EPS
Next Year EPS Consensus Estimate: $-3.23 EPS

Dividends

Dividend History for Selecta Biosciences (NASDAQ:SELB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Selecta Biosciences (NASDAQ:SELB)
Institutional Ownership Percentage: 53.53%
Insider Trades by Quarter for Selecta Biosciences (NASDAQ:SELB)
Institutional Ownership by Quarter for Selecta Biosciences (NASDAQ:SELB)
Insider Trades by Quarter for Selecta Biosciences (NASDAQ:SELB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/3/2017Lloyd P JohnstonCOOSell5,959$19.10$113,816.90View SEC Filing  
6/30/2017David SiewersCFOSell7,420$20.00$148,400.00View SEC Filing  
6/29/2017David SiewersCFOSell9,652$20.00$193,040.00View SEC Filing  
6/27/2017Peter KellerInsiderSell4,595$19.30$88,683.50View SEC Filing  
6/27/2017Timothy A SpringerDirectorBuy338,791$17.71$5,999,988.61View SEC Filing  
6/26/2017David SiewersCFOSell6,886$20.00$137,720.00View SEC Filing  
6/15/2017Lloyd P JohnstonCOOSell20,512$17.00$348,704.00View SEC Filing  
6/1/2017Timothy A SpringerDirectorBuy518$13.75$7,122.50View SEC Filing  
5/18/2017Timothy A SpringerDirectorBuy16,104$14.00$225,456.00View SEC Filing  
5/16/2017Edwin M. Kania, Jr.DirectorSell266,795$14.00$3,735,130.00View SEC Filing  
4/17/2017Lloyd P JohnstonCOOSell13,205$13.95$184,209.75View SEC Filing  
12/28/2016Takashi Kei KishimotoInsiderSell10,000$17.55$175,500.00View SEC Filing  
12/21/2016David AbrahamInsiderSell14,844$18.00$267,192.00View SEC Filing  
12/19/2016Peter KellerInsiderSell4,723$18.58$87,753.34View SEC Filing  
6/27/2016Amir NashatDirectorBuy150,000$14.00$2,100,000.00View SEC Filing  
6/27/2016Nanodimension Management LtdMajor ShareholderBuy385,000$14.00$5,390,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Selecta Biosciences (NASDAQ:SELB)
Latest Headlines for Selecta Biosciences (NASDAQ:SELB)
Source:
DateHeadline
finance.yahoo.com logoSelecta Biosciences to Participate in Upcoming Investor Conferences
finance.yahoo.com - September 20 at 8:54 AM
finance.yahoo.com logoSelecta Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : SELB-US : September 13, 2017
finance.yahoo.com - September 14 at 9:53 AM
americanbankingnews.com logoSelecta Biosciences, Inc. (SELB) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - September 13 at 8:54 PM
americanbankingnews.com logoSelecta Biosciences, Inc. (SELB) Expected to Announce Earnings of -$0.88 Per Share
www.americanbankingnews.com - September 5 at 2:14 PM
finance.yahoo.com logoSelecta Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : SELB-US : September 1, 2017
finance.yahoo.com - September 2 at 8:36 AM
finance.yahoo.com logoSelecta Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : SELB-US : September 1, 2017
finance.yahoo.com - September 2 at 8:36 AM
finance.yahoo.com logoSelecta Biosciences, Inc. :SELB-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 24 at 12:33 PM
americanbankingnews.com logoSelecta Biosciences, Inc. (SELB) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - August 19 at 6:50 PM
americanbankingnews.com logoZacks Investment Research Lowers Selecta Biosciences, Inc. (SELB) to Sell
www.americanbankingnews.com - August 16 at 6:10 AM
finance.yahoo.com logoSelecta Biosciences, Inc. – Value Analysis (NASDAQ:SELB) : August 15, 2017
finance.yahoo.com - August 15 at 9:32 PM
americanbankingnews.com logoSelecta Biosciences, Inc. (NASDAQ:SELB) Issues Quarterly Earnings Results
www.americanbankingnews.com - August 12 at 10:40 AM
finance.yahoo.com logoEdited Transcript of SELB earnings conference call or presentation 11-Aug-17 12:30pm GMT
finance.yahoo.com - August 12 at 7:44 AM
americanbankingnews.com logoSelecta Biosciences' (NASDAQ:SELB) Buy Rating Reaffirmed at Canaccord Genuity
www.americanbankingnews.com - August 11 at 6:20 PM
finance.yahoo.com logoSelecta Biosciences Announces Second Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - August 11 at 8:23 AM
finance.yahoo.com logoSelecta Biosciences to Report Second Quarter 2017 Financial Results on Friday, August 11, 2017
finance.yahoo.com - August 5 at 6:58 AM
finance.yahoo.com logoSelecta Biosciences to Present at the Canaccord Growth Conference on August 9, 2017
finance.yahoo.com - August 2 at 4:19 PM
finance.yahoo.com logoSelecta Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : SELB-US : August 1, 2017
finance.yahoo.com - August 1 at 3:44 PM
americanbankingnews.com logo Brokerages Expect Selecta Biosciences, Inc. (NASDAQ:SELB) to Announce -$0.86 Earnings Per Share
www.americanbankingnews.com - July 30 at 10:04 PM
americanbankingnews.com logoSelecta Biosciences, Inc. (NASDAQ:SELB) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - July 25 at 8:40 PM
americanbankingnews.com logoSelecta Biosciences, Inc. (NASDAQ:SELB) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - July 12 at 5:28 PM
americanbankingnews.com logoSelecta Biosciences, Inc. (NASDAQ:SELB) COO Lloyd P. Johnston Sells 5,959 Shares
www.americanbankingnews.com - July 6 at 8:04 PM
americanbankingnews.com logo-$0.86 Earnings Per Share Expected for Selecta Biosciences, Inc. (NASDAQ:SELB) This Quarter
www.americanbankingnews.com - July 6 at 6:20 PM
americanbankingnews.com logoInsider Selling: Selecta Biosciences, Inc. (NASDAQ:SELB) CFO Sells 7,420 Shares of Stock
www.americanbankingnews.com - July 5 at 7:44 PM
americanbankingnews.com logoValuEngine Upgrades Selecta Biosciences, Inc. (SELB) to "Hold"
www.americanbankingnews.com - July 1 at 9:28 AM
americanbankingnews.com logoSelecta Biosciences, Inc. (NASDAQ:SELB) CFO David Siewers Sells 9,652 Shares
www.americanbankingnews.com - June 30 at 7:29 PM
americanbankingnews.com logoSelecta Biosciences, Inc. (NASDAQ:SELB) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - June 30 at 5:08 PM
americanbankingnews.com logoInsider Selling: Selecta Biosciences, Inc. (SELB) Insider Sells 4,595 Shares of Stock
www.americanbankingnews.com - June 28 at 7:41 PM
americanbankingnews.com logoDavid Siewers Sells 6,886 Shares of Selecta Biosciences, Inc. (SELB) Stock
www.americanbankingnews.com - June 28 at 7:40 PM
americanbankingnews.com logoTimothy A. Springer Purchases 338,791 Shares of Selecta Biosciences, Inc. (SELB) Stock
www.americanbankingnews.com - June 28 at 7:20 PM
streetinsider.com logoSelecta Biosciences (SELB) Reports $50M Private Placement of Common Stock
www.streetinsider.com - June 27 at 8:13 AM
finance.yahoo.com logoSelecta Biosciences Announces $50 Million Private Placement
finance.yahoo.com - June 27 at 8:13 AM
americanbankingnews.com logo Analysts Set $26.67 Price Target for Selecta Biosciences, Inc. (SELB)
www.americanbankingnews.com - June 22 at 10:46 PM
americanbankingnews.com logoSelecta Biosciences, Inc. (SELB) COO Lloyd P. Johnston Sells 20,512 Shares
www.americanbankingnews.com - June 19 at 7:35 PM
finance.yahoo.com logoSelecta Biosciences Announces Addition of Patrick J. Zenner to Board of Directors
finance.yahoo.com - June 19 at 9:45 AM
finance.yahoo.com logoSelecta Biosciences (SELB) In Focus: Stock Moves 6.5% Higher
finance.yahoo.com - June 16 at 4:07 PM
finance.yahoo.com logoSelecta Biosciences Reports Data from Ongoing Phase 2 Trial of Lead Candidate, SEL-212, in Development for Chronic Severe Gout
finance.yahoo.com - June 15 at 4:38 PM
americanbankingnews.com logoSelecta Biosciences, Inc. (SELB) Expected to Post Earnings of -$0.86 Per Share
www.americanbankingnews.com - June 12 at 6:16 PM
finance.yahoo.com logoSelecta Biosciences Announces Upcoming Clinical Presentations
finance.yahoo.com - June 6 at 10:14 PM
finance.yahoo.com logoETFs with exposure to Selecta Biosciences, Inc. : June 6, 2017
finance.yahoo.com - June 6 at 10:14 PM
finance.yahoo.com logoSelecta Biosciences, Inc. :SELB-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 3 at 12:07 AM
americanbankingnews.com logoZacks: Analysts Set $26.67 Price Target for Selecta Biosciences Inc (SELB)
www.americanbankingnews.com - June 2 at 7:34 AM
finance.yahoo.com logoSelecta Biosciences to Present at the Jefferies Global Healthcare Conference on June 7, 2017
finance.yahoo.com - May 31 at 12:33 PM
americanbankingnews.com logoSelecta Biosciences Inc (SELB) Director Buys $225,456.00 in Stock
www.americanbankingnews.com - May 19 at 7:58 PM
americanbankingnews.com logoInsider Selling: Selecta Biosciences Inc (SELB) Director Sells 266,795 Shares of Stock
www.americanbankingnews.com - May 16 at 7:14 PM
americanbankingnews.com logo-$0.86 EPS Expected for Selecta Biosciences Inc (SELB) This Quarter
www.americanbankingnews.com - May 16 at 9:20 AM
americanbankingnews.com logo Selecta Biosciences Inc (SELB) Receives Average Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - May 16 at 8:06 AM
finance.yahoo.com logoEdited Transcript of SELB earnings conference call or presentation 11-May-17 9:00pm GMT
finance.yahoo.com - May 15 at 9:26 AM
finance.yahoo.com logoSelecta Biosciences Announces New Preclinical Gene Therapy Data at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
finance.yahoo.com - May 15 at 9:26 AM
americanbankingnews.com logoSelecta Biosciences Inc (SELB) PT Set at $25.00 by Canaccord Genuity
www.americanbankingnews.com - May 15 at 12:34 AM
americanbankingnews.com logoSelecta Biosciences Inc (SELB) Posts Quarterly Earnings Results, Beats Expectations By $0.40 EPS
www.americanbankingnews.com - May 12 at 12:14 PM

Social

Chart

Selecta Biosciences (SELB) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by MarketBeat.com Staff